Pre-made Cergutuzumab benchmark antibody ( Whole mAb Fusion, anti-CEACAM5/CD66e therapeutic antibody, Anti-CEA Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Cergutuzumab biosimilar, Whole mAb Fusion, Anti-CEACAM5/CD66e Antibody: Anti-CEA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

A recombinant fusion protein comprised of cergutuzumab, a genetically engineered human immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against carcinoembryonic antigen (CEA, CEACAM5, CD66e), linked to amunaleukin, an engineered, mutated variant form of interleukin-2 (IL-2v), with potential immunostimulating and antineoplastic activities.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-099-1mg	1mg	Inquiry
GMP-Bios-ab-099-10mg	10mg	Inquiry
GMP-Bios-ab-099-100mg	100mg	Inquiry
GMP-Bios-ab-099-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Cergutuzumab biosimilar, Whole mAb Fusion, Anti-CEACAM5/CD66e Antibody: Anti-CEA therapeutic antibody
INN Name	Cergutuzumab
Target	CD66e
Format	Whole mAb Fusion
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2015
Year Recommended	2016
Companies	Roche
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Solid tumours
Development Tech	na